GENNEX LABORATORIES LTD.

Gennex Laboratories Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the Unaudited Financial Statements (Standalone and Consolidated) for the quarter ended June 30, 2026. The meeting will also review the Limited Review Reports from the Statutory Auditor. The trading window, which was closed from July 1, 2026, will reopen 48 hours after the declaration of these financial results. The company will also discuss other business items.

Gennex Laboratories Ltd announced that Premier Fiscal Services Pvt Ltd, a promoter/promoter group entity, has pledged 25,00,000 equity shares. The pledge was created on June 09, 2026, with an expiry date of December 07, 2026, and was facilitated through BMD Securities Limited. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Premier Fiscal Services Pvt Ltd holds a total of 5,30,38,000 shares, representing 21.831% of the company's total capital. The pledged shares constitute 5.145% of the total share capital.

Gennex Laboratories Ltd has disclosed that its promoter, Premier Fiscal Services Private Limited, has pledged 25,00,000 equity shares. The pledge was created on June 9, 2026, with Vidya Tradecon Private Limited acting as the beneficiary. This action represents approximately 5.145% of the company's total share capital and 9.61% of the promoter's total holding. The shares are pledged with BMD Securities Limited as the DP. The reason for the pledge is not explicitly detailed but is typical for collateral purposes.

Premier Fiscal Services Pvt Ltd has disclosed the pledging of 25,00,000 equity shares in Gennex Laboratories Limited. The pledge was created on June 9, 2026, in favor of M/s. Vidya Tradecon Pvt. Ltd., with an expiry date of December 7, 2026. This action represents 1.029% of the total share capital and is for availing a business loan. Following this, Premier Fiscal Services' encumbered shares stand at 1,25,00,000, representing 5.145% of the total share capital.

Gennex Laboratories Ltd announced that its promoter, Premier Fiscal Services Pvt. Ltd., has pledged 25,00,000 equity shares, representing 1.029% of the total share capital, in favor of M/s. Vidya Tradecon Pvt. Ltd. This encumbrance was created on June 09, 2026, and is set to expire on December 07, 2026. The reason cited for the pledge is to avail a business loan. This action increases the promoter's already encumbered shares to 1,25,00,000, which is 5.145% of the total share capital and 4.116% of the promoter's holding.

Gennex Laboratories Limited has disclosed that its promoter, Premier Fiscal Services Pvt Ltd, has pledged 25,00,000 equity shares. The pledge was created on June 9, 2026, with Vidya Tradecon Private Limited acting as the beneficiary. This disclosure is made in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The shares are pledged as collateral for business purposes, with the encumbrance set to expire on December 07, 2026.

Gennex Laboratories Ltd's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Consolidated revenue from operations for FY26 stood at ₹172.74 Cr compared to ₹137.90 Cr in FY25. Net profit for the year was ₹20.98 Cr, up from ₹18.12 Cr in the previous year. The board meeting commenced at 4:00 PM and concluded at 7:30 PM on May 30, 2026.

Gennex Laboratories Ltd's board approved and considered the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The consolidated financial results show a revenue from operations of ₹17274.09 Lacs for the year ended March 31, 2026, compared to ₹13790.30 Lacs for the previous year. Net profit for the period stood at ₹2097.88 Lacs, up from ₹1812.49 Lacs in the previous year. The Board Meeting was held on May 30, 2026, commencing at 4:00 PM and concluding at 7:30 PM.

Gennex Laboratories Ltd clarified to the stock exchange that the recent significant price movement of its security is not attributable to any undisclosed information or announcements made by the company. The company stated that it has complied with applicable regulations and will continue to disclose any price-sensitive information to the exchange. The company believes the price movement is consistent with normal market behavior driven by external factors.

Gennex Laboratories Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial statements (standalone and consolidated) for the quarter and year ended March 31, 2026. The meeting will also address the Independent Reports of the Statutory Auditor on these financial statements. The trading window, which was closed on April 1, 2026, will reopen 48 hours after the declaration of the audited financial results.